title: [Linear-accelerator-based stereotactic irradiation for metastatic brain tumors].
abstract: To assess the safety and availability of stereotactic radiotherapy (SRT) for metastatic brain tumors, we reviewed 54 consecutive cases with a total of 118 brain metastases treated with linear-accelerator-based stereotactic irradiation (STI). Nineteen patients with a total of 27 brain tumors that were larger than 3 cm or close to critical normal tissues were treated with SRT. The marginal dose of SRT was 15-21 Gy (median 21 Gy) in 3 fractions for 3 days. The median marginal dose of stereotactic radiosurgery (SRS) was 20 Gy. Effective rates of imaging studies were 72.7% and 94.4%, and those of clinical symptoms were 46.7% and 55.6% for SRT and SRS, respectively. One-year and two-year survival rates of SRT were 40.9% and 17.6%, respectively, and the median follow-up period was 6.4 months. The one-year survival rate of SRS was 32.7%, with a median follow-up of 4.6 months. Fourteen cases (7 cases each) had recurrent tumors at STI sites. Early complications were observed in one case of SRT and 8 cases of SRS, and late complications occurred in 3 cases of SRS. There were no significant differences among effective rates, survival rates, median follow-up times, recurrence rates, and complications between SRT and SRS. We concluded that SRT is a safe, effective therapy for large or eloquent area metastases.
authors.affiliation: Department of Radiology, Okayama University Medical School.
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Takemoto
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Katsui
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yoshida
authors.forename: Kengo
authors.initials: K
authors.lastname: Himei
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kuroda
authors.forename: Susumu
authors.initials: S
authors.lastname: Kanazawa
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Sugita
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Minoru
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Fujimoto
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Hiraki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome